Status:
COMPLETED
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
University Medical Center Groningen
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Heart Failure
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabete...
Detailed Description
Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also reduce blood pres...
Eligibility Criteria
Inclusion
- Male or female subjects diagnosed with T2D ≥12 months prior to informed consent;
- eGFR ≥30 ml/min/1.73m2;
- Age \>18 years;
- HbA1c 6.5%-10.5%;
- Body Mass Index (BMI) 18.5-45.0 kg/m2;
- Blood pressure ≤160/110 and ≥90/60 at screening,
- Heart failure with New York Heart Association (NYHA) class 2-3 symptoms and ejection fraction ≥20%
- Stable dose of maximally tolerated ACE inhibitor, angiotensin receptor blocker or renin inhibitor for at least 30 days
- Stable diuretic dose for at least 30 days at the time of baseline physiological assessment
- BNP levels at baseline ≥100 pg/ml (no atrial fibrillation), ≥200 pg/ml if in atrial fibrillation
Exclusion
- Type 1 Diabetes;
- Leukocyte and/or nitrite positive urinalysis that is untreated;
- Severe hypoglycaemia within 2 months prior to screening;
- History of brittle diabetes or hypoglycaemia unawareness based on investigator judgement;
- Unstable coronary artery disease with acute coronary syndrome, percutaneous intervention or bypass surgery within 3 months;
- Clinically significant valvular disease;
- Congestive heart failure secondary to an infiltrative cardiomyopathic process (for example amyloid) or pericardial constriction;
- Uncontrolled systemic hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>110) or systemic hypotension (systolic blood pressure \< 90/60 mmHg);
- Bariatric surgery or other surgeries that induce chronic malabsorption;
- Anti-obesity drugs or diet regimen and unstable body weight three months prior to screening;
- Treatment with systemic corticosteroids;
- Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;
- Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control;
- Participation in another trial with an investigational drug within 30 days of informed consent;
- Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement;
- Liver disease, defined by serum levels of alanine transaminase, aspartate transaminase, or alkaline phosphatase \>3 x upper limit of normal as determined during screening;
- Active malignancy at the time of screening;
Key Trial Info
Start Date :
June 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2021
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT03416270
Start Date
June 28 2018
End Date
April 14 2021
Last Update
May 6 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hospital
Toronto, Ontario, Canada, M5G2N2
2
Vanderbilt University Medical Centre
Amsterdam, De Boelelaan, Netherlands, 1117
3
University Medical Center Groningen
Groningen, Netherlands